Stealth BioTherapeutics Welcomes David A. Brown, Ph.D., as Chief Scientific Officer to Lead Mitochondrial Innovations Stealth BioTherapeutics appoints Dr. David A. Brown as Chief Scientific Officer to enhance its pioneering research in mitochondrial medicine.

Stealth BioTherapeutics Welcomes David A. Brown, Ph.D., as Chief Scientific Officer to Lead Mitochondrial Innovations #USA #Needham #Stealth_BioTherapeutics #David_A._Brown #Mitochondrial_Medicine

Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough Stealth BioTherapeutics has received a significant grant from the MRC Business Engagement Fund for pioneering research into mitochondrial disease treatments via SBT-589.

Stealth BioTherapeutics Secures Grant for Mitochondrial Disease Research Breakthrough #United_Kingdom #Stealth_BioTherapeutics #Mitochondrial_Disease #Needham,_Massachusetts #SBT-589

Stealth BioTherapeutics Updates on Pipeline Developments and 2026 Goals Stealth BioTherapeutics shares vital updates on its commercial progress and R&D efforts, highlighting its 2026 strategic initiatives for mitochondrial diseases.

Stealth BioTherapeutics Updates on Pipeline Developments and 2026 Goals #United_States #Needham #Stealth_BioTherapeutics #FORZINITY #mitochondrial_diseases

Stealth BioTherapeutics Introduces Mito Assist Program and Key Distribution Partnership Stealth BioTherapeutics unveils its Mito Assist Patient Support Program and a partnership with AnovoRx to distribute FORZINITY for Barth syndrome.

Stealth BioTherapeutics Introduces Mito Assist Program and Key Distribution Partnership #USA #Needham #Stealth_BioTherapeutics #Barth_Syndrome #FORZINITY

Stealth BioTherapeutics Receives FDA Acceptance for Elamipretide NDA Resubmission for Barth Syndrome Stealth BioTherapeutics announces the FDA's acceptance of their NDA resubmission for elamipretide, targeting Barth syndrome and offering hope for treatment.

Stealth BioTherapeutics Receives FDA Acceptance for Elamipretide NDA Resubmission for Barth Syndrome #United_States #Needham #Stealth_BioTherapeutics #Barth_Syndrome #Elamipretide

Stealth BioTherapeutics Resubmits New Drug Application for Elamipretide to Treat Barth Syndrome Stealth BioTherapeutics has resubmitted a New Drug Application for elamipretide to the FDA for the treatment of Barth syndrome, a rare genetic disorder.

Stealth BioTherapeutics Resubmits New Drug Application for Elamipretide to Treat Barth Syndrome #United_States #Needham #Stealth_BioTherapeutics #Barth_Syndrome #Elamipretide

Stealth BioTherapeutics Charts New Path Forward After Delay in Barth Syndrome Treatment Approval Stealth BioTherapeutics is adjusting its strategy for elamipretide after FDA's delayed drug approval for Barth syndrome, offering new hope.

Stealth BioTherapeutics Charts New Path Forward After Delay in Barth Syndrome Treatment Approval #United_States #Needham #Stealth_BioTherapeutics #Barth_Syndrome #Elamipretide

Stealth BioTherapeutics Faces Delay in FDA Review for Barth Syndrome Treatment Stealth BioTherapeutics announces a delay in FDA action on its treatment for Barth syndrome, a rare mitochondrial disease affecting children globally. Stay informed!

Stealth BioTherapeutics Faces Delay in FDA Review for Barth Syndrome Treatment #United_States #Needham #Stealth_BioTherapeutics #Barth_Syndrome #FDA_Delay

Stealth BioTherapeutics to Unveil New Bevemipretide Findings at ARVO Meeting Stealth BioTherapeutics will present new findings on bevemipretide at the ARVO Annual Meeting, focusing on mitigating vision loss in AMD and glaucoma.

Stealth BioTherapeutics to Unveil New Bevemipretide Findings at ARVO Meeting #USA #Salt_Lake_City #AMD #Stealth_BioTherapeutics #Bevemipretide

70+ Companies Pushing Boundaries in Dry Age-Related Macular Degeneration Trials More than 70 leading companies are innovating in the dry age-related macular degeneration therapeutic space, revealing promising clinical trials for new treatments.

70+ Companies Pushing Boundaries in Dry Age-Related Macular Degeneration Trials #None #Stealth_BioTherapeutics #Alkeus_Pharmaceuticals #Ocugen

Stealth BioTherapeutics' Elamipretide Receives PDUFA Action Date Extension for Barth Syndrome Treatment Stealth BioTherapeutics announced that the FDA extended the PDUFA action date for elamipretide for Barth syndrome treatment to April 2025.

Stealth BioTherapeutics' Elamipretide Receives PDUFA Action Date Extension for Barth Syndrome Treatment #USA #Needham #Stealth_BioTherapeutics #Barth_Syndrome #Elamipretide